The FDA has appointed Vinay Prasad, a controversial oncologist known for his criticism of COVID-19 restrictions, as the new director of its Center for Biologics Evaluation and Research. This internal decision, conveyed by FDA commissioner Marty Makary, reflects a transformative period for the agency following the departure of Peter Marks, the previous head. Scott Steele had been acting in the role since Marks' exit, and Prasad's appointment could lead to changes in how biologics and vaccines are evaluated in the current healthcare landscape.
The appointment of Vinay Prasad as the new director of the FDA's Center for Biologics Evaluation and Research marks a significant leadership change amid ongoing scrutiny over vaccine policies.
With Prasad's reputation for questioning COVID-19 restrictions, his leadership might steer the FDA's approach to drug and vaccine approval towards more critical examination.
Collection
[
|
...
]